Cargando…
The optimal threshold: Baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-Year on-treatment virological response to lamivudine
BACKGROUND: HBV is still a worldwide health problem. Annually about 0.5-1.2 million patients die of HBV-related diseases such as liver cirrhosis and hepatocellular carcinoma. Lamivudine (LAM) is the first nucleoside analog used in the treatment of chronic hepatitis B. As LAM has been clinically used...
Autores principales: | Yan, Jie, Xie, Wen, Wang, Qi, Li, Yue, Feng, Xing, Cheng, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212783/ https://www.ncbi.nlm.nih.gov/pubmed/22087161 |
Ejemplares similares
-
Occult Hepatitis B Virus Among the Patients With Abnormal Alanine Transaminase
por: Makvandi, Manoochehr, et al.
Publicado: (2014) -
Liver Stiffness Measurement can Predict Liver Inflammation in Chronic Hepatitis B Patients with Normal Alanine Transaminase
por: Huang, Ling-Ling, et al.
Publicado: (2023) -
1236. Baseline liver stiffness and alanine transaminase predicts reduction in liver stiffness in people with chronic hepatitis B on tenofovir alafenamide
por: Tang, Lydia, et al.
Publicado: (2022) -
Baseline aspartate aminotransferase/alanine transaminase ratio is associated with 3-year mortality in peritoneal dialysis patients
por: Liao, Ruoxi, et al.
Publicado: (2022) -
Prognostic Value of Aspartate Transaminase/Alanine Transaminase Ratio in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma Undergoing Hepatectomy
por: Mo, Qiuyan, et al.
Publicado: (2022)